Study guide
7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
Key Takeaways Explain This Topic AI
Competency is a global legal status determined by a judge; decisional capacity is a decision-specific, time-sensitive clinical evaluation made by a licensed healthcare clinician.
Clinical capacity requires satisfying four Appelbaum pillars: (1) Understanding, (2) Appreciation of risks to self, (3) Reasoning through options, and (4) Expressing a stable Choice.
Intoxication, withdrawal, and delirium dynamically compromise capacity, mandating serial re-evaluation as physiological clearance occurs.
An 'Against Medical Advice' (AMA) discharge form is legally void if the patient lacks capacity; under the duty to protect, the clinician must initiate an emergency temporary medical hold.
Involuntary substance civil commitment (e.g., Marchman Act, Casey's Law) requires documentation of imminent self-harm/harm to others or severe grave disability, supported by objective metrics and verbatim quotes.
Last updated: September 2026
7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
Quick Answer: In acute addiction medicine, clinicians must never conflate competency with decisional capacity . Competency is a global, permanent legal status determined solely by a judge in a court of law; decisional capacity is a clinical evaluation conducted by a licensed clinician (APRN, physician) that is decision-specific and time-sensitive. Assessing capacity requires verifying the four Appelbaum pillars : (1) Understanding the medical facts, (2) Appreciation of how the diagnosis and risks apply to one's own self, (3) Reasoning logically through risks and alternatives, and (4) Expressing a stable Choice . Acute intoxication, withdrawal, or delirium transiently eliminates capacity. Crucially, a patient who lacks capacity cannot legally or ethically sign out Against Medical Advice (AMA) ; an AMA signature provides zero legal protection to the clinician. Under the duty to protect , the APRN must place the incapacitated patient on an emergency medical hold. In cases of severe, unmanageable addiction posing imminent bodily harm or grave disability, state-specific substance commitment statutes (e.g., Marchman Act, Casey's Law) provide legal mechanisms for involuntary evaluation and stabilization.
1. Decisional Capacity vs. Legal Competency: The Foundational Dichotomy
Advanced Practice Registered Nurses routinely encounter patients in acute emergency, medical, and addiction settings who refuse life-saving interventions, demand premature discharge, or exhibit severe behavioral dysregulation. Navigating these crises requires a precise grasp of healthcare jurisprudence and bioethics. CORE DICHOTOMY
- Competency vs. Clinical Decisional Capacity
- │
- ┌─────────────────────────┴─────────────────────────┐
- ▼ ▼
- [LEGAL COMPETENCY] [DECISIONAL CAPACITY]
- Judicial ruling by a judge/court • Clinical evaluation by licensed provider (APRN)
- Global legal status (all-or-nothing) • Decision-specific and time-specific
- De jure civil rights determination • De facto functional cognitive assessment
- Requires formal legal guardianship • Fluid, dynamic (can change hour-by-hour)
- Permanent unless legally revoked • Re-evaluated as intoxication/illness clears
- Legal Competency
Definition: A formal legal construct determined exclusively by a judge, magistrate, or court of law .
Scope: Competency represents a global, plenary determination regarding whether an individual possesses the legal standing to manage their affairs, execute contracts, make financial decisions, stand trial, or direct their own healthcare.
Presumption: All adults ( ≥ 18 \ge 18 ≥ 18 years of age) are legally presumed competent until adjudicated incompetent through formal probate or civil court proceedings, resulting in the appointment of a legal guardian or conservator.
Clinical Decisional Capacity
Definition: A clinical determination made by a licensed healthcare provider (APRN, physician, or qualified psychologist) regarding a patient's functional ability to make a specific healthcare decision at a specific point in time .
Dynamic Nature: Unlike competency, capacity is neither static nor global. A patient may possess the capacity to make simple, low-risk decisions (e.g., agreeing to take an oral vitamin, choosing a meal, or agreeing to blood pressure monitoring), yet concurrently lack the capacity to make complex, high-risk decisions (e.g., refusing surgical debridement for necrotizing fasciitis or refusing IV antibiotics for infective endocarditis).
The Sliding Scale of Capacity (Drane's Model): The threshold of cognitive rigor required to demonstrate decisional capacity scales proportionally with the gravity and potential lethality of the decision. When a patient's choice carries low risk and high benefit (e.g., accepting a tetanus vaccine), the threshold for capacity is modest. When a patient chooses an option that carries catastrophic morbidity or imminent mortality (e.g., refusing hospitalization during active Delirium Tremens or refusing treatment for acute ascending cholangitis), the clinician must demand the highest, most stringent standard of understanding, appreciation, and rational reasoning.
2. The Four Pillars of Decisional Capacity (The Appelbaum Criteria)
To withstand ethical scrutiny and legal challenge, an advanced practice clinical evaluation of decision-making capacity must systematically assess and document each of the four foundational pillars established by Dr. Paul Appelbaum and legal consensus: THE FOUR PILLARS OF DECISIONAL CAPACITY
- (Appelbaum Criteria)
- │
- ┌─────────────────┬──────────────┴────────────────┬─────────────────┐
- ▼ ▼ ▼ ▼
- [UNDERSTANDING] [APPRECIATION] [REASONING] [EXPRESSING CHOICE]
- Can recite facts • Applies facts to self • Logical risk/ • Clear, stable,
- Grasps nature of • Acknowledges illness is REAL benefit weighting unambiguous
- illness, risks, • Understands personal risks • Rational decision
- and benefits (not blocked by delusions) consequences • Free of paralysis
- Pillar 1: Understanding
Definition: The patient's ability to comprehend fundamental information regarding their medical condition, the proposed diagnostic and therapeutic interventions, the anticipated benefits, the known material risks, and the realistic alternatives (including the alternative of no treatment).
Assessment Technique: The clinician presents the information using simple, non-jargon language, and then asks open-ended questions instructing the patient to paraphrase: "In your own words, can you explain to me what medical problem we have found, and what treatment we are recommending?"
Failure Point: Inability to retain or articulate the basic facts due to acute cognitive blunting, encephalopathy, intellectual disability, or severe receptive aphasia.
Pillar 2: Appreciation
Definition: The patient's ability to apply the factual information to their own personal clinical situation and recognize the true clinical reality of their condition.
Assessment Technique: The clinician probes the patient's insight into their personal risk: "You understand that septic shock can be fatal; do you believe that you personally could die tonight if you leave the hospital without treatment?"
Failure Point: This is the most common failure point in acute addiction and psychiatry. A patient may display intact understanding (e.g., can recite from memory that "untreated bacterial endocarditis causes stroke and death"), but completely lacks appreciation due to profound denial, active delusions, or substance-induced grandiosity (e.g., "Those medical books don't apply to me; my immune system is protected by celestial light, so the bacteria won't hurt me" or "The nurses made up the lab results to keep me hostage" ).
Pillar 3: Reasoning
Definition: The patient's ability to engage in a rational, logical manipulation of the information to compare competing options and weigh the probable consequences of their choice.
Assessment Technique: The clinician examines the internal logic of the patient's decision: "How did you weigh the pros and cons of staying versus leaving? What makes you decide that leaving is worth the risk of dying?"
Failure Point: The patient's decision is driven by irrational, delusional, or disordered thought processes, or acute toxic impulsivity where the choice has no logical nexus to reality.
Pillar 4: Expressing a Choice
Definition: The ability to communicate a clear, definitive, and consistent choice regarding the proposed healthcare intervention.
Assessment Technique: Asking the patient directly for their decision and observing whether it remains stable over the course of the clinical encounter.
Failure Point: Severe ambivalence, continuous vacillation (e.g., agreeing to treatment one minute, demanding to leave the next, then immediately reversing again), or complete mutism/catatonia.
3. Substance-Induced Compromise of Capacity & Dynamic Re-Evaluation
Acute substance ingestion and severe withdrawal exert direct neurochemical effects that dismantle the cognitive architecture required for decision-making:
Ethanol and Sedative Intoxication: Depresses prefrontal cortical executive functioning, impairs frontal working memory, promotes severe disinhibition, and impairs cognitive processing speed. While a mild blood alcohol concentration does not automatically equate to incapacity, significant intoxication with motor incoordination, slurred speech, or cognitive clouding routinely abolishes the capacity to make complex or high-risk medical refusals.
Severe Stimulant Toxicity: Promotes paranoia, persecutory delusions, extreme impulsivity, and cognitive fragmentation, dismantling both Appreciation and Reasoning .
Substance Withdrawal Delirium (e.g., Delirium Tremens): Marked fluctuation of consciousness, global disorientation, visual hallucinations, and acute cognitive disintegration completely eliminate capacity.
The Mandate of Serial Re-Evaluation: Capacity in addictions is inherently dynamic . A patient presenting at 0200 with an ethanol level of 0.28 g/dL and acute pancreatitis may completely lack capacity to refuse admission. However, by 1000, once their blood alcohol has cleared to 0.04 g/dL, orientation is restored, and cognitive testing normalizes, decisional capacity must be re-evaluated de novo . Incapacity during acute intoxication cannot be used as justification for indefinite medical detention once the patient has metabolized the toxin and regained cognitive faculties.
4. The "Against Medical Advice" (AMA) Fallacy & The Duty to Protect
One of the most dangerous, pervasive legal misconceptions in inpatient and emergency medicine is the belief that having a patient sign an "Against Medical Advice (AMA)" document absolves the healthcare facility and the provider of malpractice liability. PATIENT DEMANDING TO DISCHARGE / ELOPE
- │
- ▼
- [MANDATORY STEP: Assess Decisional Capacity]
- │
- ┌────────────────────────┴────────────────────────┐
- ▼ ▼
- [CAPACITY INTACT] [CAPACITY IMPAIRED]
- Patient understands, appreciates, • Patient intoxicated, delirious, or
- reasons, and makes stable choice delusional; lacks appreciation/reasoning
- Fully informed of specific risks • CANNOT SIGN AMA (Legally Void)
- Patient signs AMA form • PROVIDER HAS LEGAL "DUTY TO PROTECT"
- Harm reduction discharge provided • INITIATE EMERGENCY MEDICAL HOLD
- Document entire discussion in detail • Detain, provide safety containment & treatment
- The Legal Reality of AMA Signatures
Incapacity Voids Consent: An AMA discharge is a formal refusal of medical care. Valid refusal of care requires that the individual possesses decision-making capacity . If a patient is acutely intoxicated, encephalopathic, or delirious, they are legally incapable of giving informed refusal. An AMA signature obtained from an incapacitated patient is legally void, inadmissible as a defense, and constitutes prima facie evidence of gross medical negligence and patient abandonment .
The Healthcare Provider's Duty to Protect: When a patient lacks decision-making capacity and attempts to leave the hospital into a situation of imminent peril (e.g., freezing weather, severe medical danger such as untreated Delirium Tremens, active myocardial infarction, or severe sepsis), the clinician has an affirmative, fiduciary duty to protect the patient from foreseeable harm. The provider possesses full legal and ethical authority under common-law doctrine of emergency necessity and implied consent to prevent the patient from eloping, utilizing hospital security, chemical restraint (low-dose antipsychotics), and physical restraints as an absolute last resort to maintain life safety until capacity is restored.
Practical Protocol for the Competent Patient Leaving AMA
If a patient undergoes formal evaluation and is determined to possess intact decision-making capacity despite having an active substance use disorder, they have the absolute constitutional and common-law right to refuse treatment and leave the facility. The APRN must:
Clearly articulate all risks, explicitly documenting that "leaving now carries a significant risk of permanent disability, organ failure, or death";
Offer harm reduction measures: provide prescriptions for oral antibiotics if refusing IV therapy, write a prescription for take-home Naloxone , provide clean wound dressings, and offer warm handoffs to outpatient addiction services;
Document in the medical record that the patient possessed capacity, recited the risks in their own words, and that the hospital door remains open should they choose to return at any time.
5. Involuntary Civil Commitment in Substance-Related Crises
When severe substance use renders an individual an imminent danger to themselves or others, or induces catastrophic self-neglect, legal mechanisms exist to mandate involuntary medical and psychiatric stabilization.
Psychiatric Civil Commitment vs. Substance-Specific Civil Commitment
Feature Standard Psychiatric Civil Commitment (e.g., Baker Act, CA 5150, PA 302) Substance-Specific Civil Commitment (e.g., Marchman Act, Casey's Law)
Primary Target Primary psychiatric illness (Schizophrenia, Bipolar Mania, Severe MDD) Severe Substance Use Disorder (AUD, OUD, Polysubstance)
Statutory Criteria Imminent danger to self/others, or severe grave disability resulting from a mental illness . Severe substance impairment resulting in loss of self-control, imminent self-harm/harm to others, or incapacity for survival decisions.
Substance Exclusion Clause Many state psychiatric statutes explicitly exclude sole substance intoxication/dependence as grounds for psychiatric commitment. Specifically created to fill the gap where standard psychiatric holds cannot legally hold non-psychotic, addicted individuals.
Petitioner Eligibility Law enforcement, designated mental health clinicians, APRNs, physicians. Varies: clinicians, law enforcement, or family members / loved ones (e.g., under Casey's Law or Marchman Act).
Emergency Detention Window Typically 72 hours for initial psychiatric observation and stabilization. Emergency protective hold typically 24 to 72 hours ; court hearing can mandate up to 60–90 days of residential treatment.
Core Legal Criteria for Substance Involuntary Commitment
Across jurisdictions, three universal statutory thresholds must be documented to justify involuntary civil commitment:
Loss of Self-Control / Volitional Impairment: The individual has developed such severe physiological or psychological dependence on substances that they have lost the power of self-control with respect to substance use.
Imminent Danger of Inflicting Serious Bodily Harm: Direct, objective evidence of recent threats or attempts to inflict physical harm upon themselves (e.g., intentional overdose, walking into highway traffic while intoxicated) or upon others (e.g., violent assaults).
Grave Disability / Severe Inability to Meet Basic Survival Needs: The individual's judgment is so severely compromised by chronic substance use that they are entirely incapable of providing for their own basic personal needs (nutrition, hydration, essential shelter, life-sustaining medical care) and realistic survival is threatened without involuntary intervention.
Clinical and Legal Documentation Standards
Involuntary detention and capacity denial are subject to intense legal, civil rights, and regulatory scrutiny. The APRN's documentation must be impeccably structured, avoiding broad conclusory statements like "patient lacks capacity" or "patient is combative": DEFENSIBLE DOCUMENTATION FRAMEWORK
- │
- ┌─────────────────────────────────┼─────────────────────────────────┐
- ▼ ▼ ▼
- [Objective Clinical State] [Specific Appelbaum Findings] [Alternatives & Protections]
- Vitals, BAL, tox screen • Direct verbatim quotes • Specific risks explained
- Glasgow Coma Scale / CAM • Demonstrates failed (disability, sepsis, death)
- Speech, motor control, Understanding, Appreciation, • Less restrictive measures tried
- mental status exam Reasoning, or Choice • Plan for serial re-evaluation
Document Objective Parameters: Record exact blood alcohol levels, vital signs, toxicology findings, cognitive screening scores (e.g., Montreal Cognitive Assessment or Confusion Assessment Method [CAM]), and clinical withdrawal scores (CIWA-Ar or COWS).
Record Verbatim Patient Statements: Capture direct quotes demonstrating impaired appreciation and reasoning: "When warned that leaving with an open femoral abscess could cause fatal sepsis within 24 hours, the patient stated: 'My body is immune to infection because the aliens are filtering my blood. I don't need your poison antibiotics.'"
Document Exhaustion of Less Restrictive Measures: Note all de-escalation strategies attempted (verbal redirection, offering family bedside presence, offering nicotine replacement, providing warm food/beverages, oral PRN medications) prior to implementing an emergency hold or physical restraint.
Document the Reassessment Interval: Detail the ongoing monitoring plan, ensuring the patient will be re-evaluated every 2 to 4 hours as metabolic and toxic derangements resolve.